Sonoma BioTherapeutics

company

About

Sonoma BioTherapeutics develops adoptive Treg therapies cell for autoimmune.

  • 101 - 250

Details

Last Funding Type
Series A
Last Funding Money Raised
$40M
Industries
Biotechnology,Life Science,Therapeutics
Founded date
Jan 1, 2020
Number Of Employee
101 - 250
Operating Status
Active

Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$335M
Sonoma BioTherapeutics has raised a total of $335M in funding over 2 rounds. Their latest funding was raised on Aug 4, 2021 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 4, 2021 Series B $265M 2 Detail
Sep 30, 2020 Series A $30M 3 Detail
Feb 6, 2020 Series A $40M 2 Detail

Investments

Number of Investments
Number of Lead Investments
1
0
Sonoma BioTherapeutics has made 1 investments. Their most recent investment was on Jan 11, 2022, when OneDios raised $1.20M.
Date Company Name
Round Money Raised Industry Lead Investor
Jan 11, 2022 OneDios
Seed $1.20M Customer Service

Investors

Number of Lead Investors
Number of Investors
3
Sonoma BioTherapeutics is funded by 3 investors. ARCH Venture Partners and Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series B
Lilly Asia Ventures Series B
Lyell Immunopharma Series A